Home >> Signaling Pathways >> Tyrosine Kinase >> FGFR

FGFR

FGFRs (fibroblast growth factor receptors) are transmembrane tyrosine kinase receptor. It is involved in carcinogenesis and plays an important role in cell differentiation, survival and proliferation etc.

Products for  FGFR

  1. Cat.No. Product Name Information
  2. GC62291 (Z)-Orantinib (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 ?M, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors. (Z)-Orantinib  Chemical Structure
  3. GC33519 2,5-Dihydroxybenzoic acid A benzoic acid with diverse biological activities 2,5-Dihydroxybenzoic acid  Chemical Structure
  4. GC15801 ACTB-1003 ACTB-1003 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2. ACTB-1003  Chemical Structure
  5. GC32127 Alofanib (RPT835) Alofanib (RPT835) (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Alofanib (RPT835)  Chemical Structure
  6. GC17283 AP26113 AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113  Chemical Structure
  7. GC65515 Aprutumab Aprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research. Aprutumab  Chemical Structure
  8. GC34476 ASP5878 ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity. ASP5878  Chemical Structure
  9. GC14005 AZD4547 FGFR inhibitor AZD4547  Chemical Structure
  10. GC65516 Bemarituzumab Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. Bemarituzumab  Chemical Structure
  11. GC10055 BGJ398 An FGFR inhibitor BGJ398  Chemical Structure
  12. GC19075 BLU-554 BLU-554 (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. BLU-554 has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling. BLU-554  Chemical Structure
  13. GC10833 BLU9931 FGFR4 inhibitor,potent and irreversible BLU9931  Chemical Structure
  14. GC10759 CH5183284 (Debio-1347) CH5183284 (Debio-1347) (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. CH5183284 (Debio-1347)  Chemical Structure
  15. GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF CP-547632  Chemical Structure
  16. GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy. CP-547632 hydrochloride  Chemical Structure
  17. GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. CP-547632 TFA  Chemical Structure
  18. GC62274 CPL304110 CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively. CPL304110  Chemical Structure
  19. GC15217 Danusertib (PHA-739358) A pan-Aurora kinase and Abl inhibitor Danusertib (PHA-739358)  Chemical Structure
  20. GC19399 Derazantinib Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively. Derazantinib  Chemical Structure
  21. GC32760 Dovitinib lactate (CHIR-258 lactate) Dovitinib lactate (CHIR-258 lactate) (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib lactate (CHIR-258 lactate)  Chemical Structure
  22. GC12149 E-3810 E-3810  Chemical Structure
  23. GC62696 E7090 succinate E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively. E7090 succinate  Chemical Structure
  24. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076  Chemical Structure
  25. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid  Chemical Structure
  26. GC19142 Erdafitinib A pan-FGFR tyrosine kinase inhibitor Erdafitinib  Chemical Structure
  27. GC63395 FGFR-IN-1 FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219). FGFR-IN-1  Chemical Structure
  28. GC65212 FGFR1/DDR2 inhibitor 1 FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity. FGFR1/DDR2 inhibitor 1  Chemical Structure
  29. GC64475 FGFR2-IN-2 FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively. FGFR2-IN-2  Chemical Structure
  30. GC19155 FGFR4-IN-1 FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM. FGFR4-IN-1  Chemical Structure
  31. GC62602 FGFR4-IN-5 FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research. FGFR4-IN-5  Chemical Structure
  32. GC50051 FIIN 1 hydrochloride FIIN 1 hydrochloride is a potent, irreversible, selective FGFR inhibitor. FIIN 1 hydrochloride binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN 1 hydrochloride are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively. FIIN 1 hydrochloride  Chemical Structure
  33. GC17323 FIIN-2 Irreversible inhibitor of FGFR FIIN-2  Chemical Structure
  34. GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FIIN-3  Chemical Structure
  35. GN10527 Formononetin Formononetin  Chemical Structure
  36. GN10540 Fumalic acid Fumalic acid  Chemical Structure
  37. GC64875 Gunagratinib Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer. Gunagratinib  Chemical Structure
  38. GC19187 H3B-6527 H3B-6527 (H3 Biomedicine) is a highly selective FGFR4 inhibitor with potent antitumour activity in FGF19 amplified cell lines and mice. H3B-6527  Chemical Structure
  39. GC30767 Heparan Sulfate

    Heparan sulfate (HS) is a complex, polyanionic polysaccharide ubiquitously expressed on cell surfaces and in the extracellular matrix.

    Heparan Sulfate  Chemical Structure
  40. GC14592 KW 2449 A multi-kinase inhibitor KW 2449  Chemical Structure
  41. GC15454 Lenvatinib (E7080) Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. Lenvatinib (E7080)  Chemical Structure
  42. GC36438 Lenvatinib mesylate An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate  Chemical Structure
  43. GC13848 LY2784544 Potent inhibitor of JAK2 LY2784544  Chemical Structure
  44. GC13424 LY2874455 A pan-FGFR inhibitor LY2874455  Chemical Structure
  45. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate  Chemical Structure
  46. GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279  Chemical Structure
  47. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide  Chemical Structure
  48. GC11705 Nintedanib (BIBF 1120) A VEGFR, FGFR, and PDGFR inhibitor Nintedanib (BIBF 1120)  Chemical Structure
  49. GC36745 Nintedanib esylate

    Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability .

    Nintedanib esylate  Chemical Structure
  50. GC16028 NVP-BGJ398 phosphate NVP-BGJ398 phosphate  Chemical Structure
  51. GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. ODM-203  Chemical Structure
  52. GC16327 Pazopanib (GW-786034) A multi-kinase inhibitor Pazopanib (GW-786034)  Chemical Structure
  53. GC12730 Pazopanib Hydrochloride VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor Pazopanib Hydrochloride  Chemical Structure
  54. GC44583 PD 089828 PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM). PD 089828  Chemical Structure
  55. GC12049 PD 161570 FGFR inhibitor PD 161570  Chemical Structure
  56. GC17943 PD 173074 Inhibitor of tyrosine kinase activity of fibroblast growth factor receptors PD 173074  Chemical Structure
  57. GC19279 PD-166866 PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM. PD-166866  Chemical Structure
  58. GC32915 Pemigatinib An FGFR inhibitor Pemigatinib  Chemical Structure
  59. GC31495 PF-05231023 PF-05231023 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. PF-05231023  Chemical Structure
  60. GC14396 Ponatinib (AP24534) Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534)  Chemical Structure
  61. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8  Chemical Structure
  62. GC32835 PP58 PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values. PP58  Chemical Structure
  63. GC32802 PRN1371 An irreversible pan-FGFR inhibitor PRN1371  Chemical Structure
  64. GC19154 Roblitinib

    Roblitinib (FGF-401) is a 1,8-naphthyridine pyridine derivative

    Roblitinib  Chemical Structure
  65. GC34067 Rogaratinib (BAY1163877) Rogaratinib (BAY1163877) (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib (BAY1163877)  Chemical Structure
  66. GC19317 S49076 S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. S49076  Chemical Structure
  67. GC12776 SKLB610 An inhibitor of VEGFR2 SKLB610  Chemical Structure
  68. GC62675 SM1-71 SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines. SM1-71  Chemical Structure
  69. GC10491 SSR128129E allosteric inhibitor of FGFR1, orally-active SSR128129E  Chemical Structure
  70. GC37679 SSR128129E free acid SSR128129E free acid is an orally available and allosteric FGFR inhibitor with an IC50 of 1.9 μM for FGFR1. SSR128129E free acid  Chemical Structure
  71. GC14660 SU 5402 An inhibitor of VEGFR2, FGFR1, and PDGFRβ SU 5402  Chemical Structure
  72. GC61957 SU4984 SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer. SU4984  Chemical Structure
  73. GC32805 Sulfatinib (HMPL-012) Sulfatinib (HMPL-012) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM. Sulfatinib (HMPL-012)  Chemical Structure
  74. GC19341 SUN11602 SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity. SUN11602  Chemical Structure
  75. GC49700 Takeda-6d Takeda-6d  Chemical Structure
  76. GC19156 TAS-120 TAS-120 (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. TAS-120 inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9nM; V5651=1-3nM; N550H=3.6nM; E566G=2.4nM). TAS-120  Chemical Structure
  77. GC37771 TG 100572 TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572  Chemical Structure
  78. GC37772 TG 100572 Hydrochloride TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Hydrochloride  Chemical Structure
  79. GC11622 TG 100801 TG 100801  Chemical Structure
  80. GC37773 TG 100801 Hydrochloride TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100801 Hydrochloride  Chemical Structure
  81. GC16732 TSU-68 (SU6668,Orantinib) TSU-68 (SU6668,Orantinib) (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively. TSU-68 (SU6668,Orantinib)  Chemical Structure
  82. GC34026 Tyrosine kinase-IN-1 Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. Tyrosine kinase-IN-1  Chemical Structure
  83. GC70122 Vofatamab

    Vofatamab (B-701) is a monoclonal antibody (mAb) that targets FGFR3. Vofatamab blocks the activation of both wild-type and mutated receptors. It is being studied for its potential use in metastatic urothelial carcinoma (MUC).

    Vofatamab  Chemical Structure
  84. GC70125 Vosoritide acetate

    Vosoritide (BMN 111) acetate is a natriuretic peptide receptor 2 (NPR2) agonist that can stimulate the proliferation and differentiation of chondrocytes, promoting bone growth.

    Vosoritide acetate  Chemical Structure

83 Item(s)

per page

Set Descending Direction